Vision loss occurs in DR due to the development of maculopathy, especially diabetic macular edema, and due to proliferative diabetic retinopathy. Vision loss due to DR is preventable with the ...

The phase 1 clinical trial is a multicenter, open-label, dose-escalation study to assess drug safety via intravitreal ...

Data from various retinal clinical trials suggest that there is a difference in efficacy in anti-VEGF therapies for patients with lower vision, according to a speaker here. During a presentation at ...

marking a significant milestone in the development of a potential new treatment for diabetic macular edema (DME), diabetic retinopathy (DR), and wet age-related macular degeneration (wet AMD).